A technique for pediatric total skin electron irradiation
© Bao et al; licensee BioMed Central Ltd. 2012
Received: 19 December 2011
Accepted: 20 March 2012
Published: 20 March 2012
Total skin electron irradiation (TSEI) is a special radiotherapy technique which has generally been used for treating adult patients with mycosis fungoides. Recently, two infants presented with leukemia cutis isolated to the skin requiring TSEI. This work discusses the commissioning and quality assurance (QA) methods for implementing a modified Stanford technique using a rotating harness system to position sedated pediatric patients treated with electrons to the total skin.
Methods and Results
Commissioning of pediatric TSEI consisted of absolute calibration, measurement of dosimetric parameters, and subsequent verification in a pediatric patient sized cylindrical phantom using radiographic film and optically stimulated luminance (OSL) dosimeters. The depth of dose penetration under TSEI treatment condition was evaluated using radiographic film sandwiched in the phantom and demonstrated a 2 cm penetration depth with the maximum dose located at the phantom surface. Dosimetry measurements on the cylindrical phantom and in-vivo measurements from the patients suggested that, the factor relating the skin and calibration point doses (i.e., the B-factor) was larger for the pediatric TSEI treatments as compared to adult TSEI treatments. Custom made equipment, including a rotating plate and harness, was fabricated and added to a standard total body irradiation stand and tested to facilitate patient setup under sedated condition. A pediatric TSEI QA program, consisting of daily output, energy, flatness, and symmetry measurements as well as in-vivo dosimetry verification for the first cycle was developed. With a long interval between pediatric TSEI cases, absolute dosimetry was also repeated as part of the QA program. In-vivo dosimetry for the first two infants showed that a dose of ± 10% of the prescription dose can be achieved over the entire patient body.
Though pediatric leukemia cutis and the subsequent need for TSEI are rare, the ability to commission the technique on a modified TBI stand is appealing for clinical implementation and has been successfully used for the treatment of two pediatric patients at our institution.
KeywordsPediatric total skin electron irradiation Commissioning Quality assurance Leukemia cutis
Total skin electron irradiation (TSEI) is a special radiotherapy technique which aims to deliver a uniform dose to the entire skin of a patient while sparing all other organs from a significant amount of radiation. TSEI has historically been used for the treatment of cutaneous T-cell lymphoma (mycosis fungoides), but has also been extended for the treatment of other cutaneous diseases such as Kaposi's sarcoma and scleromyxodema [1–3]. Due to the ability to achieve therapeutic dose levels to the skin with a rapid fall-off in dose beyond a shallow depth to avoid bone marrow toxicity, electron beams delivered to the total body in the energy range of 3-7 MeV (4-10 MeV at the accelerator beam exit window) have been shown to be successful for treating these superficial lesions. First proposed in the early 1950's, various TSEI treatment techniques have been evaluated and clinically implemented [4–10], and a detailed technical report on the subject has been published for the American Association of Physicists in Medicine by the American Institute of Physics .
Recently, two pediatric patients with recurrent acute myelogenous leukemia presenting with leukemia cutis (LC) were treated at the University of Texas Southwestern (UTSW) Medical Center at Dallas using TSEI. LC is an extramedullary leukemia where neoplastic leukocytes have infiltrated into the skin. Although uncommon, this skin manifestation can occur with most forms of leukemia. Patients typically present with multiple raised skin nodules and plaques. The isolated skin condition suggests treatment with superficial electron beam irradiation to the total skin and has previously been clinically described in case reports [12–15].
A particular challenge in implementing a clinical pediatric TSEI program is how to deliver a uniform dose to the total skin of a sedated infant. This report describes the dosimetric commissioning and quality assurance (QA) procedures for implementing a clinical TSEI program for the treatment of LC in pediatric patients using a modified Stanford technique [4, 16, 17]. The commissioning of fabricated setup equipment used to hold sedated pediatric patients in a modified total body irradiation (TBI) stand is also presented. To the best of our knowledge, this is the first report on the commissioning and clinical implementation of pediatric TSEI using this technique.
The pediatric TSEI technique described below is based on a modified Stanford technique, which has been used for treating adult TSEI patients at our institution. In developing a pediatric TSEI program, the same beam configuration of six dual-fields was adopted. Due to the smaller size of pediatric patients and the sedation requirement for consistent positioning, however, additional equipment and dosimetric commissioning measurements were required. The following section describes the measurements used in commissioning our adult TSEI program and the further steps required for commissioning and performing QA tests for pediatric TSEI patients.
Dosimetric commissioning and quality assurance
Adult TSEI field flatness and calibration
Absolute calibration of the machine output was performed for a single dual-field beam, using an Exradin P11 parallel-plate ion chamber under treatment conditions (330 cm SSD, 36 × 36 cm2 field size, 250° and 290° gantry angles) at a depth of dmax on the horizontal central axis according to AAPM protocol . The parallel-plate chamber was first cross-calibrated against a NIST-traceable PTW 31013 cylindrical ion chamber (PTW, Hicksville, NY) in an 18 MeV electron beam, following AAPM TG-21  and TG-51  protocols.
The entire treatment was delivered to a Rando phantom (The Phantom Laboratory, Salem, NY). Following AAPM Report 23 , the multiplication factor (B-factor) for adult patients, which relates the treatment skin dose (D S ) w to the calibration point dose (D P ) w , was determined using OneDose MOSFETs (Sicel Technologies, Inc., Morrisville, NC) placed on the surface of the Rando phantom and percent depth dose data. Conceptually, this factor represents the decrease in dose for each single field due to the contribution from the two adjacent fields. The B-factor was used to specify the dose per field per treatment cycle and required monitor units (MU) to patients, and was also used as the starting point for MU calculations to deliver doses to a pediatric patient sized phantom described below.
Phantom measurements for pediatric TSEI commissioning
Since the pediatric patient size is much smaller than the adult patient, it is necessary to determine whether the B-factor for the adult patient is applicable to the pediatric patient. A custom made cylindrical acrylic phantom of 20 cm diameter and 25 cm height was used for this evaluation. Two aluminum oxide (Al2O3) MicroStar nanoDot™ optically stimulated luminescent (OSL) dosimeters (Landauer Inc., Glenwood, IL) were placed on each of four locations (anterior, posterior, left lateral, and right lateral) at the surface of the phantom and aligned with the central axis. A surface dose of 50 cGy was delivered by manually rotating the phantom at 60° steps through each of the six TSEI positions. The required number of MUs was calculated using the B-factor for the adult patient. The dose received by the OSL nanoDots were read out using a MicroStar OSL reader with a luminescence-to-dose calibration curve applied.
XV film was sandwiched in the cylindrical acrylic phantom at mid-phantom height. The excess film was cut in a darkroom so that the film edges conformed to the circular surface of the phantom. 3 M Scotch black duct tape was wrapped around the phantom over the film edge to ensure the film was light-tight. The film plane was aligned with the horizontal central axis horizontal plane and a 50 cGy surface dose was delivered using the same technique as described above. The film was then developed and scanned using a Vidar VXR Dosimetry Pro film digitizer (VIDAR Systems Corporation, Herndon, VA). RIT113V5.2 software (Radiological Imaging Technology, Inc., Colorado Springs, CO) was used to apply a calibration curve to assess the depth dose distribution, dose profile, and isodose curves.
A custom made harness was sewn to hold the patient vertically. The harness only covers the trunk of the patient body, leaving arms and legs uncovered. The harness attaches to the rotating plate with four belts which loop through carabiner clips. The lengths of the belts were constructed such that the patient umbilicus is centered along the horizontal beam axis. The harness was made from a single layer cloth to minimize the attenuation of the electron beam yet maintain enough strength to support an infant. To ensure patient safety during treatment, the strength of the harness was verified by placing weights inside the harness while hanging on the rotating plate for at least one hour.
Two patients (17 months and 12 months old) have been treated since commissioning this pediatric TSEI technique. Each patient was scheduled to receive 16 Gy over the entire treatment course for 8 cycles as described in case reports [13, 14]. Each cycle consists of two treatment days with three dual-fields each: AP, LPO, RPO on the first day and PA, LAO, RAO on the second day. During treatment days, morning machine output quality assurance was performed using the high dose rate TSE delivery mode using a Daily QA3 detector array (Sun Nuclear Corporation, Melbourne, FL) to verify output consistency.
Prior to each treatment, the stand was moved into a preset position and the source-to-spoiler distance was measured to ensure the correct stand position. The patient was anesthetized and placed within the harness while on a gurney. The patient was monitored for hemodynamic status, pulse oximetry, and nasal end tidal carbon dioxide levels during the entire treatment. The patient was carefully lifted into place while the harness belts were clipped onto the carabiners attached to the rotating plate. The patient's head was either supported by a piece of acrylic plate placed opposite of the beam or taped in place to the harness belts. Patient arms were positioned in similar positions as for adult TSEI patients using Velcro strips which were looped around the TBI frame and attached to a Styrofoam pad taped to the patient's hand opposite of the beam (Figure 2). After the patient AP position was set, the distance from the patient to the spoiler was measured, and the rotating plate was moved along the bars of the TBI stand to the desired 25 cm spoiler-to-patient distance. The required number of MUs was delivered and then the patient was rotated to each posterior oblique position for each subsequent delivery to complete the first half of the cycle.
As part of routine quality assurance tests, OSL dosimeters were placed on the patient's skin at multiple locations. Doses for the first two days of treatment were measured and combined to give the total dose delivered during one cycle, and this was compared against the prescription dose of 200 cGy per cycle. Based on the OSL measurements, the B-factor and the required MUs were adjusted if needed in order to meet our absolute dose and dose uniformity criteria.
Phantom measurements for pediatric TSEI commissioning
OSL detector measured dose on 20 cm diameter cylindrical phantom following delivery of a prescribed 50 cGy
OSL Detector Location
NanoDot 1 Dose (cGy)
NanoDot 2 Dose (cGy)
Average Dose (cGy)
% Diff from Prescription
The dose delivered to the surface of the 20 cm diameter phantom was measured to be 53.7 cGy on average at the four locations around the phantom periphery, 7.3% higher than the nominally delivered dose. Given the intrinsic 5% accuracy of the OSL dosimeters, the dose uniformity requirement, and the fact that these measurements were not patient specific, the B-factor was not adjusted for subsequent patient MU calculations.
Patient in-vivo dosimetry
OSL detector dose measurements for cycle one of first patient
OSL Detector Location
AP + LPO + RPO Day 1 Dose (cGy)
PA + LAO + RAO Day 2 Dose (cGy)
Total Dose (cGy)
% Diff from Prescription
Posterior of head
Posterior of sternum
Posterior of Umbilicus
Posterior Left Thigh
Posterior Right Thigh
Bottom of Right Foot
OSL detector dose measurements for cycle two of first patient for reduced MUs
OSL Detector Location
AP + LPO + RPO Day 3 Dose (cGy)
PA + LAO + RAO Day 4 Dose (cGy)
Total Dose (cGy)
% Diff from Prescription
Posterior of Head
Posterior of Umbilicus
Back of Right Hand
For the second pediatric TSEI patient, the adjusted B-factor determined from phantom and in-vivo measurements in the first patient was used for MU calculations. In-vivo dosimetry was performed as in the previous patient as part of patient-specific TSEI QA. The average dose determined by the OSL detectors was 198.3 cGy, 0.8% lower than the prescription. Based on these results, no adjustment was made to the dose calculations or patient setup. However, with this patient, individual regions including the top of the head and the inner thighs exceeded our ± 10% dose uniformity criteria. After discussing with the ain's physician, an electron boost was concurrently administered to the top of the patient's head, which had visible lesions, for the second half of the treatment course based on under dosage of this region.
In this work we present the commissioning and quality assurance processes used to successfully implement a pediatric TSEI program at UTSW. With this modified Stanford technique, the sedated pediatric patient is secured by a custom made harness and rotational system attached to a common TBI stand. Though pediatric leukemia cutis and the subsequent need for TSEI are rare, the ability to commission the technique on a modified TBI stand is appealing for clinical implementation. To the best of our knowledge this is the first complete description of the commissioning and QA of pediatric TSEI using a modified Stanford technique. Rubin et al.  use a similar pediatric TSEI technique for the treatment of acute monoblastic leukemia; however, it is presented as a medical case report with an incomplete description of the irradiation technique and the commissioning and QA methods. Pepek et al.  also present a medical case report for the treatment of leukemia cutis in pediatric patients. In this work they provide a brief description of the irradiation technique, which is based on a rotating platform at extended distances. The pediatric patients were of age where they were able to stand on their own in the required positions over the course of the treatment, thus removing the need for sedation and a rotating harness system. Earley et al.  describe, to date, the most complete description of the commissioning of a pediatric TSEI technique for the treatment of a sedated acute myelocytic leukemia patient. In this technique, the sedated patient is placed on a platform that is carried to the floor for AP and PA beams and the treatment couch for oblique beams (with the gantry moved to different angles). Beam profiles were acquired at a 200 cm distance for 6 MeV electrons to assess uniformity. From the authors' description, it seems the rotating harness system and irradiation technique described in our work would facilitate a faster total treatment time without having to move a patient platform in unison with an oxygen airway, IVs, and other lines for different beam positions.
Although commissioning showed overall surface dose uniformity within ± 10% in the plane perpendicular to the central axis for an adult patient's dimensions, there are many locations which could possibly exceed this uniformity criterion. Due primarily to surface irregularities, this has also been observed in patients treated by TSEI for mycosis fungoides. Surface cavities can receive less dose than flat or convex surfaces, while higher doses may occur in areas with body protrusions [21, 22]. With the patient setup described in this work, in-vivo dosimetry demonstrated that under dose regions can occur when the skin is shielded by other body parts (inner thigh and leg regions), when the skin is shielded by patient vital sign monitoring equipment (beneath the blood pressure cuff), and at the top of the head. The inner thigh region underdose may be improved with the use of additional straps to separate the legs; however, a boost to the perineum region may still be needed at the discretion of the physician. In both UTSW clinical cases, every attempt was made to move oxygen tube and monitoring wires out of the treatment fields and away from the patient. The position of the blood pressure cuff was moved throughout the course of treatment to average out the shielding effect. As recommended in AAPM Report No. 23 , the use of boost fields required clinical judgment. Based on in-vivo dosimetry, the physician elected for a 6 MeV electron boost to the top of the head for the second patient with a 1 cm bolus since this region was under dosed during TSEI and this was the location of the isolated skin lesions.
When performing in-vivo dosimetry measurements to verify that the prescribed dose is delivered correctly and confirm dose uniformity, the choice of detector is important to consider. Thermoluminescent dosimeters have been the most commonly used for TSEI treatments due to the small volume minimizing the effect of dose gradients across the dosimeter. OSL dosimeters have recently been introduced for clinical dose measurements and have been implemented in clinical TSEI programs . OSL dosimeters were used for in-vivo measurements due to their ease of use and quick readout with the MicroStar reader system.
Patient safety is of utmost important over the course of treatment and was of primary consideration in the commissioning process. It is crucial for the sedated patient in the harness system to remain in the same position while the treatment team is outside of the vault. During commissioning, filled water jugs were placed in the harness system to demonstrate structural integrity. Velcro straps as well as paper tape were on hand in abundance to set a consistent position. At every treatment, a team including an anesthesiologist, nurse, medical physicist, and radiation therapist were present to secure the patient, monitor the patient, verify treatment settings and setup, and deliver the required radiation dose. In addition to in-vivo dosimetry, machine QA procedures were implemented and performed on each treatment day to verify proper operation in TSEI mode. This consisted of checks for output, energy, symmetry, and flatness constancy. Due to the infrequent use of this treatment technique it is important, as part of the QA protocol, to verify any changes in the system over time which would affect the patient dose, including the absolute output calibration and B-factor. At our clinic, the second pediatric TSEI case for LC occurred approximately one year following the first case. Prior to the first treatment day of the second pediatric case, a calibrated parallel plate ionization chamber was used for absolute dosimetry in TSEI mode and the output for this mode was adjusted to the value used for initial commissioning.
- Jones G, Wilson LD, Fox-Goguen L: Total skin electron beam radiotherapy for patients who have mycosis fungoides. Hematol Oncol Clin North Am 2003, 17: 1421-1434. 10.1016/S0889-8588(03)00108-4View ArticlePubMedGoogle Scholar
- Nisce LZ, Safai B, Poussin-Rosillo H: Once weekly total and subtotal skin electron beam therapy for Kaposi's sarcoma. Cancer 1981, 47: 640-644. 10.1002/1097-0142(19810215)47:4<640::AID-CNCR2820470403>3.0.CO;2-SView ArticlePubMedGoogle Scholar
- Leung SW, Hsu HC, Huang PH: Total skin electron beam irradiation in scleromyxoedema. Br J Radiol 1998, 71: 84-86.View ArticlePubMedGoogle Scholar
- Karzmark CJ: Large-field superficial electron therapy with linear accelerators. Br J Radiol 1964, 37: 302-305. 10.1259/0007-1285-37-436-302View ArticlePubMedGoogle Scholar
- Wu JM, Yeh SA, Hsiao KY, Chao MM, Hargrove I: A conceptual design of rotating board technique for delivering total skin electron therapy. Med Phys 2010, 37: 1449-1458. 10.1118/1.3315390View ArticlePubMedGoogle Scholar
- Podgorsak EB, Pla C, Pla M, Lefebvre PY, Heese R: Physical aspects of a rotational total skin electron irradiation. Med Phys 1983, 10: 159-168. 10.1118/1.595296View ArticlePubMedGoogle Scholar
- Earley L, Moeller J, O'Rear J, Leavitt DD: A method for total skin electron treatment for infants. Med Dosim 1995, 20: 243-248. 10.1016/0958-3947(95)02010-1View ArticlePubMedGoogle Scholar
- Wu JM, Leung SW, Wang CJ, Chui CS: Lying-on position of total skin electron therapy. Int J Radiat Oncol Biol Phys 1997, 39: 521-528. 10.1016/S0360-3016(97)00141-7View ArticlePubMedGoogle Scholar
- Peters VG, Jaywant SM: Implementation of total skin electron therapy using an optional high dose rate mode on a conventional linear accelerator. Med Dosim 1995, 20: 99-104. 10.1016/0958-3947(95)00013-MView ArticlePubMedGoogle Scholar
- Trump JG, Wright KA, Evans WW, Anson JH, Hare HF, Fromer JL, Jacque G, Horne KW: High energy electrons for the treatment of extensive superficial malignant lesions. The American journal of roentgenology, radium therapy, and nuclear medicine 1953, 69: 623-629.PubMedGoogle Scholar
- Karzmark CJ, Anderson J, Fessenden P, Svensson G, Buffa A, Khan FM, Wright KA: Total skin electron therapy: technique and dosimetry. Report of Task Group 30. 1987.Google Scholar
- Rubin CM, Arthur DC, Meyers G, McClain KL, Kim TH, Woods WG: Leukemia cutis treated with total skin irradiation. Cancer 1985, 55: 2649-2652. 10.1002/1097-0142(19850601)55:11<2649::AID-CNCR2820551120>3.0.CO;2-XView ArticlePubMedGoogle Scholar
- Pepek JM, Paulino AC, Briones MA, Marcus RB Jr, Esiashvili N: Role of total skin electron beam therapy for leukemia cutis in pediatric patients. Pediatr Blood Cancer 2008, 50: 1054-1055. 10.1002/pbc.21390View ArticlePubMedGoogle Scholar
- Majdzadeh N, Jain SK, Murphy MC, Dugas JP, Hager F, Abdulrahman R: Total skin electron beam radiation in a pediatric patient with leukemia cutis: A case report. Journal of Pediatric Hematology/Oncology, in press.
- Dusenbery KE, Howells WB, Arthur DC, Alonzo T, Lee JW, Kobrinsky N, Barnard DR, Wells RJ, Buckley JD, Lange BJ, Woods WG: Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the children's cancer group. Journal of Pediatric Hematology/Oncology 2003, 25: 760-768. 10.1097/00043426-200310000-00004View ArticlePubMedGoogle Scholar
- Karzmark CJ, Loevinger R, Steele RE, Weissbluth M: A technique for large-field, superficial electron therapy. Radiology 1960, 74: 633-644.View ArticlePubMedGoogle Scholar
- Karzmark CJ: Physical aspects of whole-body superficial therapy with electrons. Front Radiat Ther Oncol 1968, 2: 36-54.View ArticleGoogle Scholar
- A protocol for the determination of absorbed dose from high-energy photon and electron beams. Task Group 21, Radiation Therapy Committee, AAPM Med Phys 1983, 10: 741-771.
- Almond PR, Biggs PJ, Coursey BM, Hanson WF, Huq MS, Nath R, Rogers DW: AAPM's TG-51 protocol for clinical reference dosimetry of high-energy photon and electron beams. Med Phys 1999, 26: 1847-1870. 10.1118/1.598691View ArticlePubMedGoogle Scholar
- Van Der Merwe DG: Total skin electron therapy: A technique which can be implemented on a conventional electron linear accelerator. International Journal of Radiation Oncology Biology Physics 1993, 27: 391-396. 10.1016/0360-3016(93)90252-QView ArticleGoogle Scholar
- Niroomand-Rad A, Gillin MT, Komaki R, Kline RW, Grimm DF: Dose distribution in total skin electron beam irradiation using the six-field technique. Int J Radiat Oncol Biol Phys 1986, 12: 415-419. 10.1016/0360-3016(86)90361-5View ArticlePubMedGoogle Scholar
- Khan FM: Electron beam therapy. In The Physics of Radiation Therapy. 4th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:299-306.Google Scholar
- Esquivel C, Smith MS, Stathakis S, Gutierrez A, Shi C, Papanikolaou N: Total skin electron therapy skin dose validation using optically stimulated luminescent dosimeters [abstract]. AAPM Annual Meeting 2009. ID10746Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.